VVZ 149

Drug Profile

VVZ 149

Alternative Names: VVZ-000149; VVZ-149

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator Vivozon
  • Class Analgesics
  • Mechanism of Action Glycine plasma membrane transport protein inhibitors; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Postoperative pain

Most Recent Events

  • 01 Dec 2016 Vivozon initiates enrolment in a phase II trial for Postoperative pain in USA (NCT02992041)
  • 01 Aug 2016 Vivozon completes a phase II trial in Postoperative pain in USA (IV) (NCT02489526)
  • 01 May 2016 Vivozon initiates a phase II trial for Postoperative pain in South Korea (IV) (NCT02844725)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top